EULAR 2021: axSpA/axPsA Insights

CME

EULAR 2021: Expert Insights on Axial Spondyloarthritis and Axial Psoriatic Arthritis

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: September 02, 2021

Expiration: September 01, 2022

Atul Deodhar
Atul Deodhar, MD
Philip Mease
Philip Mease, MD, MACR

Activity

Progress
1
Course Completed

In this module, Philip Mease, MD, MACR, and Atul Deodhar, MD, MRCP, discuss key studies that will affect the management of patients with axial psoriatic arthritis (axPsA) and axial spondyloarthritis (axSpA) including new data from the CorEvitas PsA/SpA Registry revealing the high symptom burden in patients with axPsA and axSpA, the COAST trial analysis showing potential sex-related differences in axSpA in terms of the disease severity and treatment outcomes, the impact of fibromyalgia on patient-reported outcomes and quality of life, what the results of the C-OPTIMISE trial teach us about drug-free remission, the shift from a consensus-based to a data-based approach for MRI in diagnosing axSpA, and the safety and immunogenicity results in adults with autoimmune inflammatory rheumatic diseases (AIIRD) who were vaccinated for COVID-19.